Investigational drug · Phase 3
GEM
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
214
Any phase or sponsor naming "GEM"
First trial start
2022
Oct 17, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GEM", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Pancreatic Cancer
- Recurrent or Metastatic Cervical Cancer
- Pancreatic Cancer Metastatic
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- Pancreatic Adenocarcinoma Metastatic
- Pancreatic Adenocarcinoma
- Pancreatic Adenosquamous Carcinoma
- Advanced Pancreatic Carcinoma
Approved drugs for the same conditions: Pancreatic cancer · Cervical cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "GEM" as an intervention, largest first.
- Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By SurgeryPivotal-lookingStatus unknown
NSABP Foundation IncResearch network
NCT00408408 · 1,206 participants · Start Nov 2006 · Primary completion Mar 2011
Drug: bevacizumab; capecitabine and 4 more · For: Breast Cancer
Sites: Little Rock, Arkansas; Castro Valley, California; Fremont, California · 442 sites in all
- Adjuvant Pancreatic Therapy Guided by MRDPivotal-lookingRecruiting
Ruijin HospitalAcademic, hospital or other
NCT06966440 · 856 participants (planned) · Start Jun 1, 2025 · Primary completion Jun 1, 2028
Drug: adjuvant chemotherapy regimens · For: Pancreatic Adenocarcinoma Resectable
Sites: Shanghai, China
- A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 40 Years and OlderPivotal-lookingActive, not recruiting
Guangzhou Patronus Biotech Co., Ltd.Industry
NCT07311148 · 840 participants (planned) · Start Oct 23, 2025 · Primary completion Jan 2026
Drug: Low dose antigen and low dose adjuvant of LYB004; Low dose antigen and high dose adjuvant of LYB004 and 4 more · For: Herpes Zoster (HZ); Shingles; VZV and 1 more
Sites: Hengyang, China
- Modular Trial of sEphB4-HSA in EphrinB2-High Solid TumorsPivotal-lookingRecruiting
Vasgene Therapeutics, IncIndustry
NCT06493552 · 700 participants (planned) · Start Mar 15, 2025 · Primary completion Sep 2029
Drug: SEphB4-HSA; Pembrolizumab and 3 more · For: Muscle-Invasive Bladder Carcinoma; Metastatic Urothelial Carcinoma
Sites: Santa Monica, California
Astellas Pharma IncAstellas (ALPMY)
NCT05382559 · 681 participants (planned) · Start Jun 8, 2022 · Primary completion Dec 31, 2028
Drug: Setidegrasib; Cetuximab and 12 more · For: Solid Tumor
Sites: Duarte, California; Santa Monica, California; Denver, Colorado · 68 sites in all
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )Pivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT07621718 · 670 participants (planned) · Start May 22, 2026 · Primary completion Dec 30, 2028
Drug: Zoldonrasib; Placebo and 6 more · For: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC and 5 more
Sites: Phoenix, Arizona; Tucson, Arizona; New Haven, Connecticut · 25 sites in all
- GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell LymphomaPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07768943 · 620 participants (planned) · Start Sep 1, 2026 · Primary completion Jun 30, 2033
Drug: Gemcitabine (GEM); Etoposide Injection and 3 more · For: Natural Killer/T-cell Lymphoma
Sites: Shanghai, China
- Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponsePivotal-lookingRecruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT06239727 · 593 participants (planned) · Start Mar 1, 2024 · Primary completion Feb 20, 2027
Drug: PD-1 blocking antibody; Gemcitabine and 3 more · For: Nasopharyngeal Carcinoma
Sites: Fuzhou, China; Xiamen, China; Dongguan, China · 26 sites in all
- PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal CarcinomaPivotal-lookingActive, not recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT04907370 · 532 participants · Start Aug 1, 2021 · Primary completion Mar 1, 2025
Drug: PD-1 blocking antibody; Gemcitabine and 2 more · For: Nasopharyngeal Carcinoma
Sites: Beijing, China; Chongqing, China; Foshan, China · 12 sites in all
- A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic CancerPivotal-lookingNot yet recruiting
FutureGen Biopharmaceutical (Beijing) Co., LtdIndustry
NCT07383922 · 524 participants (planned) · Start Feb 28, 2026 · Primary completion Jun 30, 2030
Drug: FG-M108; nab paclitaxel and 2 more · For: Pancreatic Cancer
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- A bladder microenvironment-adaptive ceria nanozyme hydrogel enables urea-responsive intravesical chemo-immunotherapy.
Yuan Y, Yu L, Feng H, et al. · Bioact Mater 2027
- Construction of an Enzyme-Constrained Model for Escherichia coli Using GECKO Toolbox 3.0.
Huang Y, Peng J, Ren S, et al. · Methods Mol Biol 2027
- Genetically Encoded Multimeric Nanoparticles for Measuring Intracellular Diffusion and Cytoplasmic Viscosity.
Hirokane S, Lee HH, Okada Y · Methods Mol Biol 2027
- Harnessing Chlorella vulgaris-derived extracellular vesicles for potentiated cancer immunotherapy.
Meng F, Zhang C, Ma Y, et al. · Biomaterials 2027
- Fecal neuraminidase correlates with inflammatory signatures and microbiome shifts in preclinical Crohn's disease.
Mu K, Dang CP, Xue M, et al. · Gut Microbes 2026
- Phylogeny constrains and environment modulates glycoside hydrolase architecture.
Hughes AE, Castillo-Sevilla AM, Berlemont R · Curr Res Microb Sci 2026
Also in development for Pancreatic Ductal Adenocarcinoma (PDAC)
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- zoldonrasibPhase 34 trials
Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
- [18F]FAPI-74 PETPhase 33 trials
SOFIE · Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
- Precemtabart tocentecanPrecem-TcT, M9140Phase 32 trials
EMD Serono Research & Development Institute, Inc. · Metastatic Colorectal Cancer, Solid Tumors, Gastric Cancer
- VS-7375Phase 24 trials
Verastem, Inc. · G12D Mutated KRAS, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
- BT5528nuzefatide pevedotinPhase 23 trials
BicycleTx Limited · Advanced Solid Tumors, Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
- RNK08954Phase 23 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor Cancer, PDAC, KRAS G12D Mutations
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.